Living with systemic lupus erythematosus in 2024: Latin American experience based on a patient survey

Objective To assess the burden of systemic lupus erythematosus (SLE) from the perspective of patients in Latin America (LATAM) in 2024. Methods During May 2024, as part of International SLE Awareness Day, the Grupo Latinoamericano de Estudio del Lupus (GLADEL) disseminated an anonymous, bilingual (S...

Full description

Autores:
Quintana, Rosana
Bellomio, Veronica
Ugarte, Manuel
Fernandez, Diana
Nieto, Romina
Scolnik, Marina
Funes Soaje, Carmen
Alba, Paula
Saurit, Verónica
Garcia, Mercedes
Berbotto, Guillermo
Kerzberg, Eduardo
Gómez, Graciela
Pison, Cecilia
Tipo de recurso:
Fecha de publicación:
2025
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/17180
Acceso en línea:
https://hdl.handle.net/20.500.12442/17180
https://doi.org/10.1007/s10067-025-07867-1
https://link.springer.com/article/10.1007/s10067-025-07867-1
Palabra clave:
Latin America
Outcome assessment
Quality of life
Surveys and questionnaires
Systemic lupus erythematosus
Rights
openAccess
License
Attribution-NonCommercial-NoDerivatives 4.0 International
Description
Summary:Objective To assess the burden of systemic lupus erythematosus (SLE) from the perspective of patients in Latin America (LATAM) in 2024. Methods During May 2024, as part of International SLE Awareness Day, the Grupo Latinoamericano de Estudio del Lupus (GLADEL) disseminated an anonymous, bilingual (Spanish/Portuguese) online survey to patients with SLE. The survey, developed by Lupus Europe, was distributed through physicians and patient associations across LATAM and explored sociodemographic characteristics, disease features, treatments, and the impact on daily life. Results A total of 1991 responses from 21 Latin American countries were analyzed (Argentina, Brazil, the Dominican Republic, Chile, and Peru contributing the highest numbers). Most respondents were women (95.2%), with a mean age of 38.6 years (SD 11.6). Overall, 52.1% were married or partnered, 34.0% had completed secondary/vocational education, and 38.8% were employed. Regarding ethnicity, 25.5% identified as Caucasian and 34.4% as Mestizo. A prior alternative diagnosis was reported by 59.7%, with a mean age at diagnosis of 28.8 years (SD 10.6) and a median delay of 1 year (IQR 0–2). The most frequently affected organs were joints (71.4%), skin (47.4%), and kidneys (37.5%). Emotional and sexual life were negatively affected in 43.2%, and 62.1% reported impacts on education or career. Anxiety and/or depression were reported by 60%. Antimalarials, corticosteroids, immunosuppressives, and biologics were used by 80.9%, 55.7%, 59.9%, and 11.1%, respectively. Notably, 67.7% perceived their disease as under control. Conclusion Understanding patient perspectives is essential to evaluate the burden of SLE, and incorporating patient-reported experiences into decision-making should be prioritized.